Tel: +81-3-3416-0181 / Reservation(Hospital): 03-5494-7300
〈Monday~Friday(except national holiday)9A.M.〜5P.M.〉

  • Access
  • Contact Us
  • MENU

Division of Surgery

Our mission is to provide minimal invasive surgery and the most advanced medical treatments to pediatric patients.

Medical services

Our division, comprising of six surgeons and three fellows, performs more than 700 operations every year. All surgical services are available 24 hours a day. We provide post-operative intensive care in cooperation with the
neonatal intensive care unit (NICU) and the pediatric intensive care unit (PICU).

Diagnosis and treatment policy

We undertake a conference-based diagnosis for all pediatric patients to determine the best treatment strategy. We collaborate closely with other departments of the NCCHD to develop a suitable treatment plan, particularly in the treatment of solid tumors, and fetal surgical procedures.
We also carry out preoperative conference-based diagnosis for children undergoing complicated surgery, and devise preoperative and postoperative management strategies.

Specialties and target diseases

Pediatric malignant solid tumors

We provide chemotherapy, surgical therapy, combined modality therapy with radiotherapy.

Neonatal surgery (prenatal diagnosis)

We manage the surgical section of the NCCHD Perinatal Center. In particular, we specialize in surgeries for congenital diaphragmatic hernia (CDH) and have performed hundreds of successful operations in this area.

Biliary atresia, congenital bile duct dilatation

We manage a high number of cases each year in collaboration with the Center for Organ Transplantation.

Pediatric respiratory disease

We undertake a prenatal diagnosis of respiratory disease and conduct life-saving surgery immediately after birth.

Intestinal failure

We perform novel treatments for intractable functional gastrointestinal disorder.

Advanced/specialized treatments

  • Combined modality therapy for pediatric malignancy
  • Neonatal surgery and prenatal treatment
  • Digestive tract function activation therapy using probiotics
  • Attempt to ameliorate hyperbilirubinemia with intestinal failure-associated liver disease (IFALD) using omega-3 fatty acids

Return to top of page